Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac(®)) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents.

Fadlyana E, Rusmil K, Dwi Putra MG, Fulendry FP, Somantri NK, Putri AD, Sari RM, Puspita M, Dewi GP

Open source

DOI
10.3390/vaccines12080938
Published
2024 Aug 22
Container
Vaccines
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/vaccines12080938,
  title = {Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac(®)) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents.},
  author = {Fadlyana E and Rusmil K and Dwi Putra MG and Fulendry FP and Somantri NK and Putri AD and Sari RM and Puspita M and Dewi GP},
  year = {2024},
  journal = {Vaccines},
  doi = {10.3390/vaccines12080938},
  url = {https://doi.org/10.3390/vaccines12080938}
}

RIS

TY  - JOUR
TI  - Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac(®)) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents.
AU  - Fadlyana E
AU  - Rusmil K
AU  - Dwi Putra MG
AU  - Fulendry FP
AU  - Somantri NK
AU  - Putri AD
AU  - Sari RM
AU  - Puspita M
AU  - Dewi GP
PY  - 2024
JO  - Vaccines
DO  - 10.3390/vaccines12080938
UR  - https://doi.org/10.3390/vaccines12080938
ER  - 

APA

E, F., K, R., MG, D. P., FP, F., NK, S., AD, P., RM, S., M, P., & GP, D. (2024). Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac(®)) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents.. Vaccines. https://doi.org/10.3390/vaccines12080938

Source records